SPRINTEC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SPRINTEC (SPRINTEC).
Combination of ethinyl estradiol and norgestimate suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrium to prevent pregnancy.
| Metabolism | Ethinyl estradiol is metabolized primarily by CYP3A4; norgestimate is rapidly metabolized to norelgestromin and norgestrel via first-pass metabolism. |
| Excretion | Renal: approximately 50-60% (metabolites, primarily glucuronide conjugates), Fecal: approximately 30-40% (biliary excretion of metabolites), with minimal unchanged drug in urine (<5%). |
| Half-life | Ethinyl estradiol: 13 ± 3 hours (variable, influenced by CYP3A4 activity); Norgestimate: 1.5-2 hours (rapidly converted to norelgestromin); Norelgestromin: 12-20 hours (active metabolite); clinical context: dosing interval of 24 hours supports once-daily administration. |
| Protein binding | Ethinyl estradiol: >97% bound to albumin; Norgestimate/norelgestromin: 99% bound to albumin and sex hormone-binding globulin (SHBG). |
| Volume of Distribution | Ethinyl estradiol: 2.5-4.0 L/kg; Norgestimate: not determined (extensive tissue distribution); clinical meaning: reflects distribution into total body water and tissues. |
| Bioavailability | Ethinyl estradiol: 38-48% due to first-pass metabolism; Norgestimate: 100% (prodrug, rapidly hydrolyzed in gut wall and liver). |
| Onset of Action | Oral administration: contraceptive effect achieved within 7 days of consistent daily dosing; immediate if started on first day of menses. |
| Duration of Action | Contraceptive effect: sustained with daily dosing; return of fertility may be delayed up to 3-6 months after discontinuation. |
One tablet (0.25 mg norgestimate, 0.035 mg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo tablets.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment; use caution. |
| Liver impairment | Contraindicated in patients with acute or chronic hepatic dysfunction (Child-Pugh class B or C). No data for mild impairment; use with caution. |
| Pediatric use | Safety and efficacy have not been established in postmenarchal pediatric patients. Use after first menses; dosing same as adults. |
| Geriatric use | Not indicated for use in postmenopausal women. No specific dose adjustment needed for elderly patients beyond contraindications. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SPRINTEC (SPRINTEC).
| Breastfeeding | Excreted in human breast milk with milk-to-plasma ratio approximately 0.5. Potential adverse effects in nursing infant including jaundice and breast enlargement. Use during lactation not recommended unless clearly necessary. May reduce milk production and quality. |
| Teratogenic Risk | FDA Pregnancy Category X. Use contraindicated in pregnancy. First trimester: Major congenital anomalies including cardiovascular and limb defects; increased risk of neural tube defects. Second and third trimesters: Fetal genital abnormalities in females (diethylstilbestrol-like effect); potential for long-term reproductive tract changes. Postnatal: Possible increased risk of neurodevelopmental issues. |
■ FDA Black Box Warning
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptive use. Risk increases with age (>35 years) and number of cigarettes smoked. Women over 35 who smoke should not use combined oral contraceptives.
| Serious Effects |
["Thrombophlebitis or thromboembolic disorders","Cerebrovascular or coronary artery disease","Known or suspected breast cancer","Estrogen-dependent neoplasia","Undiagnosed abnormal genital bleeding","Cholestatic jaundice of pregnancy or jaundice with prior pill use","Hepatic adenoma or carcinoma","Known or suspected pregnancy","Hypersensitivity to any component"]
| Precautions | ["Increased risk of thromboembolic disorders","Increased risk of myocardial infarction and stroke, especially in smokers","Increased risk of hepatic neoplasia","Elevated blood pressure","Gallbladder disease","Carbohydrate and lipid effects","Ocular lesions","Hereditary angioedema","Chloasma"] |
Loading safety data…
| Fetal Monitoring | Pregnancy test before initiation; monthly pregnancy tests if sexually active. Ultrasound for fetal anomalies if accidental exposure occurs. Monitor for signs of thromboembolism, hypertension, and hepatic dysfunction. Fetal monitoring for growth restriction if exposure in second/third trimester. |
| Fertility Effects | Suppresses ovulation by inhibiting gonadotropin release. Reversible upon discontinuation; no evidence of permanent fertility impairment. May delay return to fertility for several cycles after cessation. |